SCHEMBL10022697

SCHEMBL10022697

CC(C)(C)c1cc(-c2cccnc2)[nH]n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.54
CYP1A2 P05177 3/20 0.54
ALDH1A1 P00352 2/20 0.54
HPGDS O60760 1/20 0.54
CYP2A6 P11509 5/20 0.49
CYP2B6 P20813 3/20 0.49
CYP2E1 P05181 2/20 0.49
ALK Q9UM73 2/20 0.47
KIF11 P52732 1/20 0.47
MAP2K4 P45985 1/20 0.47
CHEK1 O14757 2/20 0.46
CYP2C19 P33261 3/20 0.45
CYP2D6 P10635 2/20 0.45
CYP2C9 P11712 2/20 0.45
CYP19A1 P11511 1/20 0.43
LRRK2 Q5S007 2/20 0.42
PIM1 P11309 2/20 0.42
AURKA O14965 1/20 0.42
DAPK3 O43293 1/20 0.42
JAK2 O60674 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4747241 0.84 CYP3A4 (0.54) CYP3A4CYP1A2ALDH1A1HPGDSCYP2A6
SCHEMBL31053637 0.84 CYP3A4 (0.54) CYP3A4CYP1A2ALDH1A1HPGDSCYP2A6
SCHEMBL22327930 0.81 HPGDS (0.44) CYP3A4CYP1A2ALDH1A1HPGDSCYP2A6
SCHEMBL2826562 0.81 RAB9A (0.55) ALDH1A1HPGDSRETKDRTDP1
SCHEMBL28207587 0.80 ALDH1A1 (0.61) CYP3A4CYP1A2ALDH1A1HPGDSCYP2A6
SCHEMBL10311382 0.80 MITF (0.45) ALDH1A1KIF11PIM1MAP4K4PRKACA
SCHEMBL2318425 0.78 CYP3A4 (0.59) CYP3A4CYP1A2ALDH1A1HPGDSCYP2A6
SCHEMBL3078162 0.76 CYP3A4 (0.89) CYP3A4CYP1A2ALDH1A1HPGDSCYP2A6
SCHEMBL12664226 0.75 CYP3A4 (0.51) CYP3A4CYP1A2ALDH1A1HPGDSCYP2A6
SCHEMBL20575392 0.75 CYP3A4 (0.59) CYP3A4CYP1A2ALDH1A1HPGDSCYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10800760-B2 Trk inhibition NANTBIO, INC. (US) 2020-10-13 US disclosed
US-20120165322-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-28 US disclosed
US-20120165322-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10800760-B2 Trk inhibition NTRK1, NTRK3, NTRK2 CYP3A4 3433/4885CYP1A2 3040/4885ALDH1A1 3905/4885
US-20120165322-A1 RHO KINASE INHIBITORS ROCK1, ROCK2, RHOA CYP3A4 2215/4885CYP1A2 1116/4885ALDH1A1 2674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.